Comments on: Novartis Strikes Deal With Thailand Over Gleevec http://www.pharmalot.com/2008/01/novartis-strikes-deal-with-thailand-over-gleevec/ News, Comment and Conversation Fri, 10 Feb 2012 21:32:48 +0000 http://wordpress.org/?v=2.6.2 By: Imatinib/Gleevec(R) in Thailand gratis. Danaergeschenk? « AntiNovartisInnovation http://www.pharmalot.com/2008/01/novartis-strikes-deal-with-thailand-over-gleevec/#comment-150297 Imatinib/Gleevec(R) in Thailand gratis. Danaergeschenk? « AntiNovartisInnovation Mon, 11 Feb 2008 09:21:48 +0000 http://www.pharmalot.com/2008/01/novartis-strikes-deal-with-thailand-over-gleevec/#comment-150297 [...] Thailand gratis. Danaergeschenk? Veröffentlicht in 11. Februar 2008 von antinova Nach dieser Meldung hat Novartis eingelenkt und verschenkt jetzt in Thailand das Krebsmittel Imatinib, damit die [...] [...] Thailand gratis. Danaergeschenk? Veröffentlicht in 11. Februar 2008 von antinova Nach dieser Meldung hat Novartis eingelenkt und verschenkt jetzt in Thailand das Krebsmittel Imatinib, damit die [...]

]]> By: Joana Ramos http://www.pharmalot.com/2008/01/novartis-strikes-deal-with-thailand-over-gleevec/#comment-126478 Joana Ramos Fri, 01 Feb 2008 00:40:51 +0000 http://www.pharmalot.com/2008/01/novartis-strikes-deal-with-thailand-over-gleevec/#comment-126478 Less media attention has been given to certain key issues about access to Glivec and intricacies of the international philanthropic program GIPAP ( Glivec International Patient Assistance Program) that Novartis set up in 2001. From the very start, Novartis decided that Glivec would be sold at a global price, i.e. at the same base price worldwide, not matter what the economic situation of any individual country might be. In some countries, especially in the developing world, the price may be even higher due to import taxes. This marked one of the first times that a global, exorbitant price was set for a new drug. However, eligibility for GIPAP , which was originally planned just for developing countries, has been linked to the poverty level of each nation. This despite the fact that after US approval, the Novartis' Gleevec assistance program for uninsured American patients allowed income of up to US$43,000 to qualify for free medicine. Less media attention has been given to certain key issues about access to Glivec and intricacies of the international philanthropic program GIPAP ( Glivec International Patient Assistance Program) that Novartis set up in 2001.

From the very start, Novartis decided that Glivec would be sold at a global price, i.e. at the same base price worldwide, not matter what the economic situation of any individual country might be.

In some countries, especially in the developing world, the price may be even higher due to import taxes. This marked one of the first times that a global, exorbitant price was set for a new drug. However, eligibility for GIPAP , which was originally planned just for developing countries, has been linked to the poverty level of each nation.

This despite the fact that after US approval, the Novartis’ Gleevec assistance program for uninsured American patients allowed income of up to US$43,000 to qualify for free medicine.

]]>